Source: Google NewsPublished on 2020-12-29
Related Articles:
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
- Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Global Neuroprotection Methods, Drugs, Markets and Competitive Landscape Report 2020: Profiles of 141 Companies that have a Neuroprotective Product or Oroducts Along with 126 Collaborations - ResearchAndMarkets.com - Odessa American December 29, 2020 Global Neuroprotection Methods, Drugs, Markets and Competitive Landscape Report 2020: Profiles of 141 Companies that have a Neuroprotective Product or Oroducts Along with 126 Collaborations - ResearchAndMarkets.com Odessa American
- Global Neuroprotection Methods, Drugs, Markets and Competitive Landscape Report 2020: Profiles of 141 Companies that have a Neuroprotective Product or Oroducts Along with 126 Collaborations - ResearchAndMarkets.com - WV News December 29, 2020 Global Neuroprotection Methods, Drugs, Markets and Competitive Landscape Report 2020: Profiles of 141 Companies that have a Neuroprotective Product or Oroducts Along with 126 Collaborations - ResearchAndMarkets.com WV News
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
- Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction: Parkinson’s changes us in many ways: it makes us stronger by…
- Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction: Parkinson’s changes us in many ways: it makes us stronger by…
- Life with Parkinson’s in the Time of COVID-19: April is Parkinson’s Awareness Month April 1, 2020 “The measure of who we are is what we do with what we have.” Vince Lombardi “When you have exhausted all possibilities, remember this: you haven’t.” Thomas Edison Précis: A different world exists today than it did just a few weeks ago, all driven by the COVID-19 pandemic. The virus seemingly favors the elderly who have a pre-existing disease(s); however,…
- Life with Parkinson’s in the Time of COVID-19: April is Parkinson’s Awareness Month April 1, 2020 “The measure of who we are is what we do with what we have.” Vince Lombardi “When you have exhausted all possibilities, remember this: you haven’t.” Thomas Edison Précis: A different world exists today than it did just a few weeks ago, all driven by the COVID-19 pandemic. The virus seemingly favors the elderly who have a pre-existing disease(s); however,…
- Neuroprotection Methods, Drugs, Markets and Companies Research Repoer 2019: Profiles of 140 Companies with 126 Collaborations - ResearchAndMarkets.com - Business Wire August 1, 2019 Neuroprotection Methods, Drugs, Markets and Companies Research Repoer 2019: Profiles of 140 Companies with 126 Collaborations - ResearchAndMarkets.com Business WireDUBLIN--(BUSINESS WIRE)--The "Neuroprotection - Methods, Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ...
- The drug development pipeline for Parkinson’s December 2, 2020 # # # # For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of drug development. Such projects are difficult, however, as the landscape is broad and dynamic – lots of different approaches being applied and new entrants continually entering the arena.…
- Neuroprotection Methods, Drugs, Markets and Competitive Landscape Report 2019 with Profiles of 138 Companies & Their 123 Collaborations - GlobeNewswire May 16, 2019 Neuroprotection Methods, Drugs, Markets and Competitive Landscape Report 2019 with Profiles of 138 Companies & Their 123 Collaborations GlobeNewswireDublin, May 16, 2019 (GLOBE NEWSWIRE) -- The "Neuroprotection - Methods, Drugs, Markets and Companies" report from Jain PharmaBiotech has been ...
- CMT-3: A better option than doxy? November 22, 2020 # # # # It has been reported by multiple independent research groups that tetracycline-based antibiotic drugs (such as doxycycline) have exhibited neuroprotective properties in models of Parkinson’s. Translation of these preclinical findings into the clinic has, however, been difficult. In addition, concerns have been expressed that long-term use of such agents could bring forward the emergence of antibiotic resistance…
- Neuroprotection Methods, Drugs, Markets and Competitive Landscape Report 2019 with Profiles of 138 Companies & Their 123 Collaborations - Yahoo Finance May 16, 2019 Neuroprotection Methods, Drugs, Markets and Competitive Landscape Report 2019 with Profiles of 138 Companies & Their 123 Collaborations Yahoo FinanceThe "Neuroprotection - Methods, Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
- Very Keynesian: Cell painting November 25, 2020 # # # # Our ability to grow cells in culture (in petri dishes and flasks in laboratories) has been critical to our efforts to learn more about the biology of Parkinson’s and to screen for novel potential therapies. Recently, researchers have employed more sophisticated methods of characterising cells in culture, to achieve greater insights. These effort have led to…
- TGF-beta: The Parkinson’s superfamily? December 12, 2020 # # # # A lot of Parkinson’s research has focused on a neurotrophic factor called glial cell-derived neurotrophic factor (or GDNF). But GDNF only represents a small fraction of a much larger class of neurotrophic factors, called the Transforming growth factor-β (TGF-β) superfamily. Recently, researchers have been investigating some of the other TGF-β family members in preclinical models of…
- PARP-kinson’s goes chlorogenic December 20, 2020 # # # # For a long time it was been reported that coffee may be able to reduce the risk of developing Parkinson’s, but the mechansim by which this association could be occurring has remained elusive. Now researchers from South Korea have discovered a biological pathway that could help to explain the protective association. It involves a protein called…